Skip To Main Content
Mallika Singh on Muck Rack

Mallika Singh

Verified
Brooklyn
As seen in: Daily Mail, Nature, The Times of India, Wiley Online Library, Cell Reports, Cell Press, This is Money, ThePrint, WION News, The Stanford Daily, FandomWire and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mallika

Contact Mallika, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

|
By Ida Aronchik, Sumit Kar, Yongxian Zhuang, Ethan Ahler, Lick Pui Lai, Vidya Devanathadesikan Seshadri, Marie Ménard, Mark P. Labrecque, Julien Dilly, Eejung Kim, Lingyan Jiang, Jason Yano, Urszula Wasko, Brad Sickler, Xing Wei, Kyle J. Seamon, Kian-Huat Lim, Matthew Holderfield, Elsa Quintana, Aparna Hegde, Zeena Salman, Alexander N. Starodub, Alexander Spira, Wungki Park, David Hong, Minal Barve, Meredith S. Pelster, David Sommerhalder, Salman Punekar, Ignacio Garrido-Laguna, Brian Wolpin, Anirban Maitra, Steve Kelsey, Jacqueline Smith, Kevin Lin, Andrew J. Aguirre, Mallika Singh Verified, Ashenafi Bulle, Biswadeep Nayak, Ciara Helland, Sean Bredeson, Brett Garrick, Yevgeniy Gindin, W. Clay Gustafson
| Nature Verified
Abstract Daraxonrasib is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of N, H and KRAS. We previously reported encouraging efficacy in a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinically active dose levels in patients with previously treated, RAS mutant metastatic pancreatic adenocarcinoma (PDAC), providing the basis for confirmatory evaluation in the randomized phase 3 RASolute 302 clinical trial.
Open in Who Shared Issue with article?

Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS -mutant colorectal cancer

|
By Philip H. Choi, Julia Meredith, Malvika Sharma, Xiaoping Chen, Juan Qiu, Vladimir Markov, Elisa de Stanchina, Mallika Singh Verified, Neal Rosen
| Cell Reports Verified
ArticleVolume 45, Issue 7117559Open access Affiliations & Notes 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 3Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA 4Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA Article Info Publication History: Received November 22, 2025; Revised April 14, 2026;...
Open in Who Shared Issue with article?

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma

|
By Rodrigo Entrialgo-Cadierno, Konstantina Morali, Iker Feliu, Yingyun Wang, James Evans, Mariana Yáñez-Bartolomé, Inés López Verified, Irati Macaya, Cristina Cueto-Ureña, Daniel Sin-Coscujuela, Yaiza Senent, Jose M. Herranz, Rashi Raghulan, Javier Vaquero, Jesus M Banales, Teresa Macarulla, Mariano Ponz-Sarvise, Ximo Pechuan-Jorge, Elisabeth Guruceaga, Alyssa Schumpp, Alia García, Alyssa Kim, Benjamin Herzberg, Nilofer S. Azad, Aparna Hegde, Tian Tian, Ida Aronchik, Mallika Singh Verified, Jingjing Jiang, Silve Vicent
| Cell Press Verified
Keywords cholangiocarcinoma biliary tract cancer KRAS oncogene RAS(ON) multi-selective inhibitor targeted therapy therapy resistance drug combinations preclinical models Introduction The KRAS oncogene is one of the most broadly mutated oncogenes in humans and a key driver in lung, colorectal, and pancreatic cancer, the three most common causes of death by cancer in the US.1,2 KRAS mutations also occur in less prevalent, but equally fatal, cancers such as those of the biliary tract, esophagus,...
Open in Who Shared Issue with article?
See all 257 licensed articles (266 Total)